ArticleBMJ open2021

Rationale and design of the ADAPT-TAVR trial: a randomised comparison of edoxaban and dual antiplatelet therapy for prevention of leaflet thrombosis and cerebral embolisation after transcatheter aortic valve replacement.

Hanbit Park et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.